Drug Trial Radar · NCT00981045
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,561
Actual
Start
Aug 2009
Primary completion
Jul 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- American Regent, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.
Conditions
- Iron Deficiency Anemia
- Impaired Renal Function
Interventions
Ferric Carboxymaltose (FCM)Drug
2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
Iron Sucrose (Venofer)Drug
5 doses of 200 mg for a total cumulative dose of 1000 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.Time frame: Day 56
- Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.Time frame: Day 120
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Luitpold Pharmaceuticals, Inc.
Norristown, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.